Femoropopliteal

Diabetes and Peripheral Vascular Disease: Old Drugs, New Evidence

This paper, recently published in JAHA, showed that patients with type 2 diabetes mellitus exhibiting lower-limb vascular disease...

The Key We Are Overlooking in Peripheral Vascular Disease

To change the prognosis of peripheral vascular disease patients, a referral for supervised exercise is paramount. This...

ESC 2020 | Rivaroxaban Might Reduce Cardiac Cerebral and Peripheral Events

Adding rivaroxaban to the standard treatment might reduce events incidence in lower limbs, heart, and brain, in...

Common Femoral Artery Endarterectomy Plus Angioplasty in Critical Ischemia

This prospective study analyzed patients with critical lower limb ischemia (due to complex, multiple lesions in several...

Virtual ACC 2020 | VOYAGER PAD: Rivaroxaban Superior to Aspirin in Preventing Events

In patients with peripheral artery disease undergoing revascularization, the combination of rivaroxaban (Xarelto) and low doses of...

Virtual ACC 2020 | COMPASS Sub-Analysis: Diabetes Increases the Benefit of Rivaroxaban Combined with AAS

In patients with stable coronary or peripheral artery disease, diabetes increases the benefit of combining low doses...

New European Guidelines on the Management of Lower Limb Acute Ischemia

Clinical practice guidelines are usually tedious and, frankly, while a lot of people make an enormous effort...

Felling Reassured with Paclitaxel Coated Devices in Peripheral Artery Disease

This big analysis shows rapid absorption of paclitaxel coated devices for PCI in femoropopliteal territory, which reassures...